Getting off GLP-1s: what the rebound data actually says

What did @titatots actually say?

Tita describes gaining 40 pounds after starting new birth control, then using semaglutide (she calls it "ozumbic," meaning Ozempic) to lose it. Her main claim is that instead of quitting cold turkey, she did a supervised taper: every other week, then monthly, then every other month. She says her weight stayed stable, gained 7 pounds on her honeymoon, took one dose, and was back to baseline in a week and a half. Her conclusion: "semaglutide has helped me create healthy, sustainable habits."

That is a fairly specific protocol, and she credits her doctor throughout. She is not selling anything. She is describing her personal experience with a real clinical approach. Worth taking seriously, with some caveats.

Does the science back this up?

Mostly, yes, and more than you might expect from a TikTok video. The rebound concern she raises is real and well-documented. The tapering strategy her doctor used has clinical logic behind it, even if the exact schedule she describes is not a formally validated protocol.

The STEP 1 trial extension (Wilding et al., 2022, New England Journal of Medicine) followed patients who stopped semaglutide after 68 weeks. Within one year of stopping, they regained about two-thirds of their lost weight. That is the "rebound effect" she heard about. It happens because semaglutide suppresses appetite centrally, and when you remove it, hunger returns. Her doctor's description of "insatiable hunger" if you quit cold turkey lines up with what patients in withdrawal studies report.

On the taper approach: there is no published randomized trial specifically on every-other-week or monthly dosing as a maintenance strategy. But the pharmacokinetics of semaglutide (half-life of roughly 7 days) suggest that stretching doses does gradually reduce plasma levels rather than causing an abrupt drop. That is the logic. The evidence is not definitive, but the reasoning is not invented either.

What did they get wrong (or right)?

She got the rebound risk right. She got the general tapering concept right. Where things get softer is her implicit suggestion that the 7-pound honeymoon gain coming off in "a week and a half" after one dose was primarily a semaglutide effect. That timeline is plausible if a significant portion of that gain was water retention and inflammation from alcohol and restaurant food, not actual fat. Semaglutide does not burn 7 pounds of fat in 10 days at any dose.

She also attributes her initial 40-pound gain entirely to birth control. Hormonal contraceptives can cause weight gain, but 40 pounds is on the extreme end of what research supports. Studies on modern low-dose pills typically show modest weight changes of 1 to 4 pounds (Gallo et al., 2014, Cochrane Database). It is possible she had an underlying condition like PCOS (mentioned in her hashtags) that the birth control unmasked or worsened. That is a more complicated story than she tells.

Her framing of "healthy, sustainable habits" is the one claim worth scrutinizing. Did the drug help her build habits, or did it suppress appetite enough that good habits felt easier? Those are different mechanisms with different long-term implications. To her credit, she does not oversell this as a permanent fix.

What should you actually know?

GLP-1 receptor agonists like semaglutide are not a permanent metabolic reset. The STEP 1 extension data is clear: when the drug stops, appetite largely returns. The question is whether patients can sustain behavioral changes in that window. Some do. Many do not. Tita appears to be in the group that maintained routines, which matters a lot.

Tapering strategies are being used clinically, but they are not yet backed by formal guidelines. The American Diabetes Association and Obesity Society do not currently publish an official maintenance taper protocol for semaglutide. If your doctor recommends one, that is reasonable clinical judgment, not a proven standard of care.

If you have PCOS, the GLP-1 picture is actually more interesting. Small trials (Jensterle et al., 2022, Frontiers in Endocrinology) have shown semaglutide may improve insulin resistance and androgen levels in PCOS patients beyond just weight loss. That context matters for someone like Tita, even if she does not fully spell it out.

One more thing: the rapid weight loss she describes in the first week was almost certainly not fat loss. That was fluid and inflammation reduction. Managing expectations around what those early numbers mean is important for anyone starting a GLP-1.

Bottom line: should you trust this video?

More than average for this genre. She cites her doctor repeatedly, does not claim this is a cure, and accurately names the biggest risk (rebound). The personal framing keeps her honest. The gaps are in the 40-pound birth control claim and the attribution of that rapid honeymoon recovery to the drug. Those are worth knowing about, but they do not make the core story wrong.